OAM
CRNX icon

Oppenheimer Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Oppenheimer Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$789K Buy
21,730
+3,944
+22% +$176K 0.01% 780
2025
Q4 		$828K Buy
17,786
+12,489
+236% +$556K 0.01% 718
2025
Q3 		$221K Buy
+5,297
New +$169K ﹤0.01% 1074
2025
Q1 		– Sell
-5,038
Closed -$258K – 1140
2024
Q4 		$258K Buy
5,038
+822
+19% +$46K ﹤0.01% 1018
2024
Q3 		$215K Buy
+4,216
New +$217K ﹤0.01% 1082
2024
Q2 		– Sell
-4,276
Closed -$200K – 1156
2024
Q1 		$200K Buy
+4,276
New +$167K ﹤0.01% 1039

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Oppenheimer Asset Management's CRNX Position: Q1 2026 in Review

Oppenheimer Asset Management increased its Crinetics Pharmaceuticals (CRNX) stake by 22% in Q1 2026, buying an estimated $176K and bringing the position to 21,730 shares worth $789K. The position accounts for 0.01% of the portfolio, ranked #780.

Oppenheimer Asset Management first reported a position in CRNX in Q1 2024 and has held it in 6 quarters since. The position peaked at $828K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Oppenheimer Asset Management held 21,730 shares of Crinetics Pharmaceuticals worth $789K as of Q1 2026.
  • Oppenheimer Asset Management bought 3,944 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $176K.
  • Crinetics Pharmaceuticals made up 0.01% of Oppenheimer Asset Management's portfolio in Q1 2026, its #780 holding.
  • Oppenheimer Asset Management first reported a position in Crinetics Pharmaceuticals in Q1 2024 and has held it in 6 quarters since.
  • Oppenheimer Asset Management's Crinetics Pharmaceuticals position peaked at $828K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Oppenheimer Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.